Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus.

MLA

Hamann, Christine, et al. “Sclerostin Antibody Treatment Improves Bone Mass, Bone Strength, and Bone Defect Regeneration in Rats with Type 2 Diabetes Mellitus.” Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research, vol. 28, no. 3, Mar. 2013, pp. 627–38. EBSCOhost, https://doi.org/10.1002/jbmr.1803.

APA

Hamann, C., Rauner, M., Höhna, Y., Bernhardt, R., Mettelsiefen, J., Goettsch, C., Günther, K.-P., Stolina, M., Han, C.-Y., Asuncion, F. J., Ominsky, M. S., & Hofbauer, L. C. (2013). Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research, 28(3), 627–638. https://doi.org/10.1002/jbmr.1803

Chicago

Hamann, Christine, Martina Rauner, Yvonne Höhna, Ricardo Bernhardt, Jan Mettelsiefen, Claudia Goettsch, Klaus-Peter Günther, et al. 2013. “Sclerostin Antibody Treatment Improves Bone Mass, Bone Strength, and Bone Defect Regeneration in Rats with Type 2 Diabetes Mellitus.” Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research 28 (3): 627–38. doi:10.1002/jbmr.1803.